<style face="normal" font="default" size="100%">460 Efficacy of adding anti-PD1 immunotherapy to dabrafenib + trametinib (DT) at progression in BRAFv600e mutated anaplastic thyroid carcinoma (BRAFm-ATC)</style>

Drupal-HighWire